Retrospective Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2016; 22(20): 4908-4917
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4908
Primary hepatic epithelioid angiomyolipoma: A malignant potential tumor which should be recognized
Jie Liu, Cheng-Wu Zhang, De-Fei Hong, Ran Tao, Yuan Chen, Min-Jie Shang, Yu-Hua Zhang
Jie Liu, Cheng-Wu Zhang, De-Fei Hong, Ran Tao, Min-Jie Shang, Yu-Hua Zhang, Department of Hepatopancreatobiliary Surgery and Minimally Invasive Surgery, Zhejiang Provincial People’s Hospital, Hangzhou 310014, Zhejiang Province, China
Yuan Chen, Department of Pathology, Zhejiang Provincial People’s Hospital, Hangzhou 310014, Zhejiang Province, China
Author contributions: Liu J and Zhang CW contributed equally to this work; Liu J collected and analyzed the data, and drafted the manuscript; Zhang CW designed and supervised the study; Tao R revised the manuscript; Chen Y was responsible for pathological analysis; Shang MJ and Zhang YH provided analytical oversight; and Hong DF provided academic support; all authors have read and approved the final version to be published.
Institutional review board statement: The study was reviewed and approved by the Zhejiang Provincial People’s Hospital Institutional Review Board.
Informed consent statement: The study participant provided informed written consent for this study.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other people or organizations that can inappropriately influence our work, and there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled “Primary hepatic epithelioid angiomyolipoma: A malignant potential tumor which should be recognized”.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at zcw1989@sina.com. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Cheng-Wu Zhang, MD, Department of Hepatopancreatobiliary Surgery and Minimally Invasive Surgery, Zhejiang Provincial People’s Hospital, 158 Shangtang Road, Hangzhou 310014, Zhejiang Province, China. zcw1989@sina.com
Telephone: +86-571-85893419 Fax: +86-571-85131448
Received: January 20, 2016
Peer-review started: January 22, 2016
First decision: March 7, 2016
Revised: March 20, 2016
Accepted: March 30, 2016
Article in press: March 30, 2016
Published online: May 28, 2016
Core Tip

Core tip: Hepatic epithelioid angiomyolipoma (HEAML) is very rare tumor that is often misdiagnosed because of atypical symptoms and imaging manifestation. The diagnosis can be made based upon characteristic pathological and immunohistochemical criteria. Traditionally, it is thought to be a benign tumor and is therefore largely ignored. Thus, it is important to improve the recognition of HEAML. This is the first article to analyze the clinicopathological data and imaging results of HEAML comprehensively by combining our four patients with other cases reported worldwide. In fact, HEAML has malignant potential and should be followed closely after surgery.